Minimal AnticoaGulation EvaluatioN To aUgment heMocompatibility - The MAGENTUM 1 Study

The HeartMate 3 Left Ventricular Assist system (LVAS) has demonstrated enhanced hemocompatibility, with absence of de-novo pump thrombosis. However, clinically observed bleeding-related adverse events continue to remain significantly burdensome. We hypothesized that the enhanced hemocompatibility of the HeartMate 3 LVAS allows the safe use of decreased anticoagulation intensity, potentially decreasing bleeding-related adverse events.

Source: The Journal of Heart and Lung Transplantation - March 31, 2018 Category: Transplant Surgery Authors: I. Netuka, P. Iv ák, Z. Tučanová, S. Gregor, O. Szárszoi, P. Sood, J. Rimsans, J.M. Connors, M.R. Mehra Source Type: research